<div id="readability-page-1"><p>M&amp;T Bank Corp boosted its stake in  United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 171.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 3,142 shares of the biotechnology company's stock after buying an additional 1,985 shares during the period. M&amp;T Bank Corp's holdings in United Therapeutics were worth $1,531,000 at the end of the most recent quarter.</p><ul><li>The Top 3 Stock Picks at the World’s Greatest Hedge Fund</li></ul><p>Other institutional investors and hedge funds have also recently bought and sold shares of the company. Wilmington Savings Fund Society FSB raised its holdings in  United Therapeutics by 125.6% in the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company's stock valued at $37,000 after buying an additional 49 shares during the period.  Harbor Capital Advisors Inc. purchased a new stake in  United Therapeutics in the 4th quarter valued at about $48,000.  Abich Financial Wealth Management LLC purchased a new stake in  United Therapeutics in the 3rd quarter valued at about $44,000.  WealthCollab LLC raised its holdings in  United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company's stock valued at $30,000 after buying an additional 38 shares during the period.  Finally, Rakuten Securities Inc. raised its holdings in  United Therapeutics by 76.7% in the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company's stock valued at $30,000 after buying an additional 46 shares during the period. 94.08% of the stock is currently owned by hedge funds and other institutional investors. </p><div><p><span></span><span>Get <strong>United Therapeutics</strong> alerts:</span></p></div><h2>Key United Therapeutics News</h2><p>Here are the key news stories impacting United Therapeutics this week:</p><ul>   <li><span>Positive Sentiment: </span>Investors are focusing on United Therapeutics’ pipeline and growth catalysts, especially encouraging Tyvaso data in IPF and optimism around ralinepag’s blockbuster potential, which could support future revenue growth. <i></i><span>UTHR Q1 Earnings Miss Estimates, Shares Jump on Strong Outlook</span></li>    <li><span>Positive Sentiment: </span>Royal Bank of Canada kept an <strong>outperform</strong> rating and only slightly lowered its price target to $701 from $707, signaling continued confidence in upside from current levels. <i></i><span>RBC lowers price target on UTHR</span></li>    <li><span>Neutral Sentiment: </span>United Therapeutics held its Q1 2026 earnings call, which investors are likely parsing for commentary on Tyvaso, ralinepag, and the company’s growth outlook. <i></i><span>Q1 2026 Earnings Call Transcript</span></li>    <li><span>Negative Sentiment: </span>Q1 results missed estimates, with EPS of $5.82 versus expectations of $7.00 and revenue of $781.5 million versus $797.4 million expected; revenue also declined 1.6% year over year. <i></i><span>Q1 2026 Financial Results</span></li>    <li><span>Negative Sentiment: </span>Insider selling may be weighing on sentiment: CEO Martine Rothblatt sold 9,500 shares and EVP Paul Mahon sold 8,300 shares, both sizable reductions in their holdings. <i></i><span>Rothblatt SEC filing</span> <i></i><span>Mahon SEC filing</span></li> </ul><h2>United Therapeutics Stock Performance</h2><ul><li>Liquidia: Court victory the awakening of an industry giant?</li></ul><p>UTHR stock opened at $564.94 on Friday. The company's 50 day moving average price is $550.17 and its 200 day moving average price is $501.37. United Therapeutics Corporation has a fifty-two week low of $272.12 and a fifty-two week high of $609.35. The firm has a market capitalization of $23.98 billion, a price-to-earnings ratio of 20.85, a PEG ratio of 1.77 and a beta of 0.60. </p><p>United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing analysts' consensus estimates of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The firm had revenue of $781.50 million for the quarter, compared to analysts' expectations of $797.40 million. During the same quarter in the previous year, the company posted $6.63 earnings per share. The firm's quarterly revenue was down 1.6% on a year-over-year basis.  Equities analysts forecast that  United Therapeutics Corporation will post 27.4 EPS for the current fiscal year. </p><h2>Analyst Ratings Changes</h2><ul><li>Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential</li></ul><p>UTHR has been the topic of several research analyst reports. Morgan Stanley  set a $516.00 price objective on shares of United Therapeutics in a report on Thursday. HC Wainwright boosted their price objective on shares of United Therapeutics from $600.00 to $660.00 and gave the company a &#34;buy&#34; rating in a report on Tuesday, March 31st. Bank of America boosted their price target on shares of United Therapeutics from $569.00 to $626.00 and gave the stock a &#34;neutral&#34; rating in a research note on Tuesday, March 31st. TD Cowen boosted their price target on shares of United Therapeutics from $575.00 to $660.00 and gave the stock a &#34;buy&#34; rating in a research note on Monday, March 30th. Finally, UBS Group boosted their price target on shares of United Therapeutics from $655.00 to $705.00 and gave the stock a &#34;buy&#34; rating in a research note on Thursday, March 5th. Eleven investment analysts have rated the stock with a Buy rating and two have assigned  a Hold rating to the company's stock. According to MarketBeat, the stock  has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $619.42.</p><p><b>Read Our Latest Analysis on UTHR</b></p><h2>Insider Buying and Selling</h2><p>In related news, CFO James Edgemond sold 10,000 shares of the company's stock in a transaction that occurred on Monday, March 23rd. The stock was sold at an average price of $527.48, for a total value of $5,274,800.00. Following the completion of the transaction, the chief financial officer directly owned 18,876 shares of the company's stock, valued at $9,956,712.48. This represents a 34.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Michael Benkowitz sold 22,500 shares of the company's stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $474.65, for a total value of $10,679,625.00. The SEC filing for this sale provides additional information. Insiders sold 485,155 shares of company stock valued at $266,370,949 over the last ninety days. 10.30% of the stock is currently owned by corporate insiders. </p><h2>About United Therapeutics</h2> (Free Report)<p>United Therapeutics Corporation <span>NASDAQ: UTHR<span></span></span> is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than United Therapeutics</li><li>Buffett Spent 60 Years Ignoring Tech and the Bill Is Coming Due</li><li>Excited About Gold But Unsure of Its Trajectory? Try These 3 Approaches</li><li>Dollar at a 3-Year Low: 3 Exporters Quietly Printing Money</li><li>Water Infrastructure: Why This Boring Sector Could Get Exciting</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VVRIUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VVRIUg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in United Therapeutics Right Now?</h2><p>Before you consider United Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and United Therapeutics wasn't on the list.</p><p>While United Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

UTHR

<p>M&T Bank Corp increased its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 171.6% in Q4, owning 3,142 shares valued at $1.53 million. Other institutional investors also raised their holdings. Despite a recent earnings miss, positive sentiment surrounds United Therapeutics due to its pipeline and growth potential. Analysts have mixed views, with price targets ranging from $516 to $660. UTHR stock opened at $564.94, with a market cap of $23.98 billion and a P/E ratio of 20.85.</p>

Market Beat

United Therap

M&T Bank

Rakuten Group, Inc.

Lotte Group

ROYAL BANK OF CANADA

Liquidia Tech

Morgan Stanley

Bank of America

M & T BANK CORP DEP SHS REPSTG 1/400TH INT PERP SER K

M & T BANK CORP PERP NON CUM PFD FIXED FLTG RATE SER H

M & T BANK CORP DEP SHS EA REP 1/400TH SHS SERIES J

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

M&T Bank Corp Raises Stock Holdings in United Therapeutics Corporation $UTHR